EUVIMEDEUVIMED entdecken
Crossref

Targeting Mediator Kinase Attenuates Cardiac Hypertrophy by Regulating Enhancer Utilization

Rachel A Minerath iD, Kayla M Henry iD, Anna K Leinheiser iD, Olha M Koval iD, Allison M Hagenow iD, Duane D Hall iD, Colleen C Mitchell iD, Chad E Grueter iD

Journal of the American Heart Association · 03.11.2026 · 15 (21)

DOI: 10.1161/jaha.125.045861 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the American Heart Association, erschienen am 03.11.2026. Verfasst von Rachel A Minerath und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Division of Cardiovascular Medicine, Francois M. Abboud Cardiovascular Research Center, Fraternal Order of Eagles Di…. Hauptthemen laut MEDLINE: Cardiomegaly, Myocytes, Cardiac, Protein Kinase Inhibitors, Enhancer Elements, Genetic. Die Arbeit nennt 54 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Cardiac hypertrophy is characterized by extensive transcriptional remodeling that contributes to the progression of heart failure. Preclinical models demonstrate that therapies targeting hypertrophic responses can mitigate disease severity. Recent evidence shows that failing human and murine hearts exhibit elevated mediator kinase expression, sufficient to drive eccentric hypertrophy and heart failure through activation of hypertrophic gene programs. Mediator kinase inhibition suppresses oncogenic transcription by altering enhancer utilization, suggesting similar mechanisms may attenuate pathological remodeling in the heart. This study investigates whether mediator kinase inhibition can blunt cardiomyocyte hypertrophy, offering a potential therapeutic strategy for heart failure.

Methods

Two structurally unrelated mediator kinase inhibitors, Senexin A (SxnA) and CCT251545, were tested in neonatal rat cardiomyocytes. Hypertrophy was assessed by cell size measurements, RNA sequencing, and H3K27ac chromatin immunoprecipitation sequencing.

Results

Mediator kinase inhibition significantly reduced hypertrophic growth, attenuating cell size increases induced by phenylephrine (PE) and endothelin‐1. Transcriptomic profiling revealed a dose‐dependent suppression of PE‐induced differentially expressed genes in Senexin A‐treated cells. Mechanistically, PE stimulation enhanced RNA polymerase II pause release, whereas Mediator kinase inhibition did not alter this process. Epigenomic analysis showed that PE markedly increased the number of super‐enhancers relative to vehicle treatment, while co‐treatment with Senexin A reduced the total number of active enhancers. Nearest‐neighbor analysis linked putative regulatory enhancers to key PE‐responsive genes, and these enhancer signatures were blunted by SxnA.

Conclusions

These findings demonstrate that Mediator kinase inhibition counteracts hypertrophic growth and transcriptional reprogramming, highlighting its potential as a therapeutic strategy to modulate pathological gene regulation in cardiac hypertrophy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CardiomegalyMyocytes, CardiacProtein Kinase InhibitorsEnhancer Elements, GeneticAnimalsRatsSuper EnhancersCells, CulturedRats, Sprague-DawleyAnimals, Newborn

Stichwörter der Autor:innen

cardiac hypertrophyepigeneticsmediator kinasetranscriptional enhancers

Substanzen

Protein Kinase Inhibitors

Autor:innen und Institutionen

  • Department of Internal Medicine, Division of Cardiovascular Medicine, Francois M. Abboud Cardiovascular Research Center, Fraternal Order of Eagles Diabetes Research Center University of Iowa Iowa City IA USA.
  • Department of Pharmacology University of Iowa Iowa City IA USA.
  • Interdisciplinary Program in Genetics University of Iowa Iowa City IA USA.
  • Department of Mathematics University of Iowa Iowa City IA USA.

ORCID-Profile: Rachel A Minerath, Kayla M Henry, Anna K Leinheiser, Olha M Koval, Allison M Hagenow, Duane D Hall, Colleen C Mitchell, Chad E Grueter

Zitieren

APA

Minerath, R. A., Henry, K. M., Leinheiser, A. K., Koval, O. M., Hagenow, A. M., Hall, D. D., Mitchell, C. C., & Grueter, C. E. (2026). Targeting Mediator Kinase Attenuates Cardiac Hypertrophy by Regulating Enhancer Utilization. Journal of the American Heart Association, 15(21). https://doi.org/10.1161/jaha.125.045861

Vancouver

Minerath RA, Henry KM, Leinheiser AK, Koval OM, Hagenow AM, Hall DD, et al. Targeting Mediator Kinase Attenuates Cardiac Hypertrophy by Regulating Enhancer Utilization. Journal of the American Heart Association. 2026;15(21). doi:10.1161/jaha.125.045861

BibTeX
@article{Minerath2026,
  author = {Minerath, Rachel A and Henry, Kayla M and Leinheiser, Anna K and Koval, Olha M and Hagenow, Allison M and Hall, Duane D and Mitchell, Colleen C and Grueter, Chad E},
  title = {Targeting Mediator Kinase Attenuates Cardiac Hypertrophy by Regulating Enhancer Utilization},
  journal = {Journal of the American Heart Association},
  year = {2026},
  volume = {15},
  number = {21},
  doi = {10.1161/jaha.125.045861}
}
Kostenlos starten →